The JCO Podcast hosted by Dr. Shannon Westin features discussions of new and noteworthy results publ
TRANSCRIPT This JCO Podcast provides observations and commentary on the JCO article “Progression of
This podcast summarizes the findings of the Lunenburg Lymphoma Biomarker Consortium systematic evalu
This podcast discusses the work of Sheetz and colleagues describing the impact of centralization of
Dr. Osama Rahma, an Assistant Professor of Medicine at Harvard Medical School, Dana-Farber Cancer In
This JCO Podcast provides observations and commentary on the JCO article, "Treatment of Childhood Na
This JCO Podcast provides observations and commentary on the JCO article “Maintaining Outstanding Ou
This JCO Podcast provides observations and commentary on the JCO article “Dose-Adjusted EPOCH-R Comp
This JCO Podcast provides observations and commentary on the JCO article “Erlotinib Versus Gemcitabi
This JCO Podcast provides observations and commentary on the JCO article 'Late Relapses in Patients
This JCO Podcast provides observations and commentary on the JCO article “Resumption of Immune Check
This JCO Podcast provides observations and commentary on the JCO article “PET Score Has Greater Prog
This podcast provides observations and commentary on the JCO article "Randomized, Double-Blind, Phas
This JCO Podcast provides observations and commentary on the JCO article “Therapy-Related Cardiac Ri
This JCO Podcast provides observations and commentary on the JCO article Durable Tumor Regression an
This JCO Podcast provides observations and commentary on the JCO article Gonadal Functioning and Per
This JCO podcast provides observations and commentaries on the JCO article entitled "Indeterminate P
This JCO Podcast provides observations and commentary on the JCO article “Tamoxifen pharmacogenetics
This JCO Podcast provides observations and commentary on the JCO article “Impact of Surveillance Ima
This JCO Podcast provides observations and commentary on the JCO article, "Impact of Baseline Steroi
Read the related article "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuz
